enGene Inc. (ENGN)
NASDAQ: ENGN
· Real-Time Price · USD
3.70
0.09 (2.49%)
At close: Aug 15, 2025, 3:59 PM
3.68
-0.54%
After-hours: Aug 15, 2025, 04:10 PM EDT
2.49% (1D)
| Bid | 3.52 |
| Market Cap | 189.09M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -28.25M |
| EPS (ttm) | -1.63 |
| PE Ratio (ttm) | -2.27 |
| Forward PE | -1.67 |
| Analyst | Buy |
| Ask | 3.85 |
| Volume | 29,031 |
| Avg. Volume (20D) | 84,417 |
| Open | 3.54 |
| Previous Close | 3.61 |
| Day's Range | 3.54 - 3.76 |
| 52-Week Range | 2.65 - 11.00 |
| Beta | -0.41 |
About ENGN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ENGN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ENGN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts5 months ago
+1.19%
EnGene Holdings shares are trading higher after Pi...
Unlock content with
Pro Subscription
9 months ago
+1.91%
EnGene Holdings shares are trading higher. The company announced it generated approximately $60 million in proceeds from a private placement.
1 month ago · seekingalpha.com
enGene Holdings: Looking For An End To The 2025 Decline (Downgrade)enGene Holdings Inc.'s lead asset, detalimogene voraplasmid, continues to show early promise in non-muscle invasive bladder cancer, with pivotal LEGEND trial data expected in late 2025. Financially, E...
2 months ago · businesswire.com
enGene Reports Second Quarter 2025 Financial Results and Provides Business UpdateBOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for ...
